Publikationer av Kristina Westerlund
Refereegranskade
Artiklar
[1]
M. Oroujeni et al., "Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing Xenografts," Journal of Nuclear Medicine, vol. 63, no. 7, s. 1046-1051, 2022.
[2]
H. Tano et al., "Comparative Evaluation of Novel Lu-177-Labeled PNA Probes for Affibody-Mediated PNA-Based Pretargeting," Cancers, vol. 13, no. 3, 2021.
[3]
K. Westerlund et al., "Stability Enhancement of a Dimeric HER2-Specific Affibody Molecule through Sortase A-Catalyzed Head-to-Tail Cyclization," Molecules, vol. 26, no. 10, 2021.
[4]
A. Myrhammar et al., "Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargeting," Scientific Reports, vol. 10, no. 1, 2020.
[5]
A. Abouzayed et al., "Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer," Pharmaceutics, vol. 12, no. 10, 2020.
[6]
C. Stiller et al., "Fast and Efficient Fc-Specific Photoaffinity Labeling To Produce Antibody-DNA Conjugates," Bioconjugate chemistry, vol. 30, no. 11, s. 2790-2798, 2019.
[7]
K. Westerlund et al., "Site-specific conjugation of recognition tags to trastuzumab for peptide nucleic acid-mediated radionuclide HER2 pretargeting," Biomaterials, vol. 203, s. 73-85, 2019.
[8]
A. Vorobyeva et al., "Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy," Scientific Reports, vol. 8, no. 1, 2018.
[9]
K. Westerlund et al., "Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting : In Vivo Proof of Principle," Journal of Nuclear Medicine, vol. 59, no. 7, s. 1092-1098, 2018.
[10]
M. Altai et al., "Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting : Development of an optimized conjugation protocol and 177Lu labeling," Nuclear Medicine and Biology, vol. 54, s. 1-9, 2017.
[11]
H. Honarvar et al., "Evaluation of the first Sc-44-labeled Affibody molecule for imaging of HER2-expressing tumors," Nuclear Medicine and Biology, vol. 45, s. 15-21, 2017.
[12]
M. Altai et al., "Comparative evaluation of Lu-177-HP2 and In-111-HP2, secondary agents for affibody-based PNA-mediated radionuclide pretargeting," European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, s. S237-S237, 2016.
[13]
H. Honarvar et al., "Development and application of first Sc-44-labeled Affibody molecule," European Journal of Nuclear Medicine and Molecular Imaging, vol. 43, s. S177-S177, 2016.
[14]
H. Honarvar et al., "Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors," Theranostics, vol. 6, no. 1, s. 93-103, 2016.
[15]
K. Westerlund et al., "Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody Molecules," Molecular Pharmaceutics, vol. 13, no. 5, s. 1668-1678, 2016.
[16]
K. Westerlund et al., "Design, Preparation, and Characterization of PNA-Based Hybridization Probes for Affibody-Molecule-Mediated Pretargeting," Bioconjugate chemistry, vol. 26, no. 8, s. 1724-1736, 2015.
[17]
H. Honarvar et al., "Feasibility of Affibody molecule-based PNA-mediated pretargeting," European Journal of Nuclear Medicine and Molecular Imaging, vol. 42, s. S101-S102, 2015.
Kapitel i böcker
[18]
M. Altai et al., "Preparation of Conjugates for Affibody-Based PNA-Mediated Pretargeting," i Methods in Molecular Biology, : Humana Press Inc., 2020, s. 283-304.
Icke refereegranskade
Artiklar
[19]
M. Oroujeni et al., "Combined treatment of mice bearing HER2-expressing xenografts by trastuzumab and Affibody-mediated PNA-based pretargeting improves their survival," European Journal of Nuclear Medicine and Molecular Imaging, vol. 48, no. SUPPL 1, s. S158-S158, 2021.
[20]
M. Oroujeni et al., "Comparative evaluation of novel Lu-177-labeled PNA conjugates for affibody mediated PNA-based pretargeting," European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. SUPPL 1, s. S344-S344, 2020.
[21]
M. Altai et al., "Design and evaluation oflactosaminated cetuximabas a clearing agent for antibody-based PNA-mediated pretargeting," European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. SUPPL 1, s. S343-S344, 2020.
[22]
M. Altai et al., "A novel method for conjugation of PNA to antibodies for radionuclide based pretargeting : proof of principal," European Journal of Nuclear Medicine and Molecular Imaging, vol. 45, s. S648-S648, 2018.
[23]
A. Vorobyeva et al., "Development of a PET Imaging Approach for Selection of Patients for Affibody-Based PNA-Mediated Pretargeted Radionuclide Therapy," European Journal of Nuclear Medicine and Molecular Imaging, vol. 45, s. S104-S104, 2018.
[24]
A. Vorobyeva et al., "Feasibility of Z Domain-Mediated Conjugation of PNA to Antibodies for Radionuclide Pretargeting," European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, s. S559-S560, 2017.
[25]
M. Altai et al., "Pretargeted radionuclide therapy of HER2-expressing SKOV-3 human xenografts using an Affibody molecule-based PNA-mediated pretargeting," European Journal of Nuclear Medicine and Molecular Imaging, vol. 44, s. S142-S142, 2017.
Övriga
[26]
E. Duray et al., "Development of an anti-CD38 single domain antibody fragment mediated PNA-based pretargeting strategy," (Manuskript).
[27]
M. Gestin et al., "Evaluation of the impact of length of peptide nucleic acid probes for tumor pretargeting," (Manuskript).
Senaste synkning med DiVA:
2024-04-28 00:23:10